CD47 and non-Hodgkin lymphoma: In pre-clinical experiments using Raji cells as a disseminated non-Hodgkin lymphoma (NHL) model, the humanized IgG4 isotype of CD47-blocking antibody Hu5F9-G4 synergized with rituximab to eliminate Raji cells, resulting in extended survival of mice, although Hu5F9-G4 alone showed only a modest survival benefit compared with that of the control [61].